Histone deacetylases inhibitor MS-275 suppresses human esophageal squamous cell carcinoma cell growth and progression via the PI3K/Akt/mTOR pathway

Shanshan Ma, Tengfei Liu, Ling Xu, Yaping Wang, Jiankang Zhou, Tuanjie Huang, Peng Li, Hongtao Liu, Yanting Zhang, Xinkui Zhou, Yuanbo Cui, Xingxing Zang, Yuming Wang, Fangxia Guan

Research output: Contribution to journalArticle

Abstract

Esophageal squamous cell carcinoma (ESCC) is a malignant tumor with low survival rate, so new therapies are urgently needed. Histone deacetylases (HDACs) play a critical role in tumorigenesis, and HDACs inhibition is a potential therapeutic target in ESSC. In our study, we evaluated the effect and molecular mechanism of MS-275 (an inhibitor of HDACs) on ESCC cells. We found that HDAC1 and HDAC2 were overexpressed in ESCC tissues and related with clinical pathological features of patients with ESCC. MS-275 markedly reduced HDAC1 and HDAC2 expression, whereas increased the level of AcH3 and AcH2B. MS-275 suppressed proliferation and clonogenicity of ESCC cells in a concentration-dependent manner. In addition, MS-275 induced apoptosis, arrested cell cycle, and inhibited migration, epithelial–mesenchymal transition, and sphere-forming ability of ESCC cells in vitro. Moreover, p-Akt1 and p-mTOR were downregulated by MS-275. Finally, MS-275 significantly inhibited tumor growth in vivo. Taken together, HDAC1 and HDAC2 are associated with the progression of ESCC, and MS-275 hinders the progression and stemness of ESCC cells by suppressing the PI3K/Akt/mTOR pathway. Our findings show that MS-275 inhibits ESCC cells growth in vitro and in vivo, which is a potential drug for the ESCC therapy.

Original languageEnglish (US)
Pages (from-to)22400-22410
Number of pages11
JournalJournal of Cellular Physiology
Volume234
Issue number12
DOIs
StatePublished - Jan 1 2019

Fingerprint

Histone Deacetylases
Cell growth
Phosphatidylinositol 3-Kinases
Growth
Tumors
entinostat
Epithelial Cells
Esophageal Squamous Cell Carcinoma
Cell- and Tissue-Based Therapy
Neoplasms
Cell Cycle
Carcinogenesis
Down-Regulation
Survival Rate
Cells
Tissue
Apoptosis

Keywords

  • cancer stemness
  • esophageal squamous cell carcinoma
  • MS-275
  • PI3K/Akt/mTOR
  • progression

ASJC Scopus subject areas

  • Physiology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Histone deacetylases inhibitor MS-275 suppresses human esophageal squamous cell carcinoma cell growth and progression via the PI3K/Akt/mTOR pathway. / Ma, Shanshan; Liu, Tengfei; Xu, Ling; Wang, Yaping; Zhou, Jiankang; Huang, Tuanjie; Li, Peng; Liu, Hongtao; Zhang, Yanting; Zhou, Xinkui; Cui, Yuanbo; Zang, Xingxing; Wang, Yuming; Guan, Fangxia.

In: Journal of Cellular Physiology, Vol. 234, No. 12, 01.01.2019, p. 22400-22410.

Research output: Contribution to journalArticle

Ma, Shanshan ; Liu, Tengfei ; Xu, Ling ; Wang, Yaping ; Zhou, Jiankang ; Huang, Tuanjie ; Li, Peng ; Liu, Hongtao ; Zhang, Yanting ; Zhou, Xinkui ; Cui, Yuanbo ; Zang, Xingxing ; Wang, Yuming ; Guan, Fangxia. / Histone deacetylases inhibitor MS-275 suppresses human esophageal squamous cell carcinoma cell growth and progression via the PI3K/Akt/mTOR pathway. In: Journal of Cellular Physiology. 2019 ; Vol. 234, No. 12. pp. 22400-22410.
@article{6cce813cbc294026aaf2e3140247c78c,
title = "Histone deacetylases inhibitor MS-275 suppresses human esophageal squamous cell carcinoma cell growth and progression via the PI3K/Akt/mTOR pathway",
abstract = "Esophageal squamous cell carcinoma (ESCC) is a malignant tumor with low survival rate, so new therapies are urgently needed. Histone deacetylases (HDACs) play a critical role in tumorigenesis, and HDACs inhibition is a potential therapeutic target in ESSC. In our study, we evaluated the effect and molecular mechanism of MS-275 (an inhibitor of HDACs) on ESCC cells. We found that HDAC1 and HDAC2 were overexpressed in ESCC tissues and related with clinical pathological features of patients with ESCC. MS-275 markedly reduced HDAC1 and HDAC2 expression, whereas increased the level of AcH3 and AcH2B. MS-275 suppressed proliferation and clonogenicity of ESCC cells in a concentration-dependent manner. In addition, MS-275 induced apoptosis, arrested cell cycle, and inhibited migration, epithelial–mesenchymal transition, and sphere-forming ability of ESCC cells in vitro. Moreover, p-Akt1 and p-mTOR were downregulated by MS-275. Finally, MS-275 significantly inhibited tumor growth in vivo. Taken together, HDAC1 and HDAC2 are associated with the progression of ESCC, and MS-275 hinders the progression and stemness of ESCC cells by suppressing the PI3K/Akt/mTOR pathway. Our findings show that MS-275 inhibits ESCC cells growth in vitro and in vivo, which is a potential drug for the ESCC therapy.",
keywords = "cancer stemness, esophageal squamous cell carcinoma, MS-275, PI3K/Akt/mTOR, progression",
author = "Shanshan Ma and Tengfei Liu and Ling Xu and Yaping Wang and Jiankang Zhou and Tuanjie Huang and Peng Li and Hongtao Liu and Yanting Zhang and Xinkui Zhou and Yuanbo Cui and Xingxing Zang and Yuming Wang and Fangxia Guan",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/jcp.28805",
language = "English (US)",
volume = "234",
pages = "22400--22410",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Histone deacetylases inhibitor MS-275 suppresses human esophageal squamous cell carcinoma cell growth and progression via the PI3K/Akt/mTOR pathway

AU - Ma, Shanshan

AU - Liu, Tengfei

AU - Xu, Ling

AU - Wang, Yaping

AU - Zhou, Jiankang

AU - Huang, Tuanjie

AU - Li, Peng

AU - Liu, Hongtao

AU - Zhang, Yanting

AU - Zhou, Xinkui

AU - Cui, Yuanbo

AU - Zang, Xingxing

AU - Wang, Yuming

AU - Guan, Fangxia

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Esophageal squamous cell carcinoma (ESCC) is a malignant tumor with low survival rate, so new therapies are urgently needed. Histone deacetylases (HDACs) play a critical role in tumorigenesis, and HDACs inhibition is a potential therapeutic target in ESSC. In our study, we evaluated the effect and molecular mechanism of MS-275 (an inhibitor of HDACs) on ESCC cells. We found that HDAC1 and HDAC2 were overexpressed in ESCC tissues and related with clinical pathological features of patients with ESCC. MS-275 markedly reduced HDAC1 and HDAC2 expression, whereas increased the level of AcH3 and AcH2B. MS-275 suppressed proliferation and clonogenicity of ESCC cells in a concentration-dependent manner. In addition, MS-275 induced apoptosis, arrested cell cycle, and inhibited migration, epithelial–mesenchymal transition, and sphere-forming ability of ESCC cells in vitro. Moreover, p-Akt1 and p-mTOR were downregulated by MS-275. Finally, MS-275 significantly inhibited tumor growth in vivo. Taken together, HDAC1 and HDAC2 are associated with the progression of ESCC, and MS-275 hinders the progression and stemness of ESCC cells by suppressing the PI3K/Akt/mTOR pathway. Our findings show that MS-275 inhibits ESCC cells growth in vitro and in vivo, which is a potential drug for the ESCC therapy.

AB - Esophageal squamous cell carcinoma (ESCC) is a malignant tumor with low survival rate, so new therapies are urgently needed. Histone deacetylases (HDACs) play a critical role in tumorigenesis, and HDACs inhibition is a potential therapeutic target in ESSC. In our study, we evaluated the effect and molecular mechanism of MS-275 (an inhibitor of HDACs) on ESCC cells. We found that HDAC1 and HDAC2 were overexpressed in ESCC tissues and related with clinical pathological features of patients with ESCC. MS-275 markedly reduced HDAC1 and HDAC2 expression, whereas increased the level of AcH3 and AcH2B. MS-275 suppressed proliferation and clonogenicity of ESCC cells in a concentration-dependent manner. In addition, MS-275 induced apoptosis, arrested cell cycle, and inhibited migration, epithelial–mesenchymal transition, and sphere-forming ability of ESCC cells in vitro. Moreover, p-Akt1 and p-mTOR were downregulated by MS-275. Finally, MS-275 significantly inhibited tumor growth in vivo. Taken together, HDAC1 and HDAC2 are associated with the progression of ESCC, and MS-275 hinders the progression and stemness of ESCC cells by suppressing the PI3K/Akt/mTOR pathway. Our findings show that MS-275 inhibits ESCC cells growth in vitro and in vivo, which is a potential drug for the ESCC therapy.

KW - cancer stemness

KW - esophageal squamous cell carcinoma

KW - MS-275

KW - PI3K/Akt/mTOR

KW - progression

UR - http://www.scopus.com/inward/record.url?scp=85071185292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071185292&partnerID=8YFLogxK

U2 - 10.1002/jcp.28805

DO - 10.1002/jcp.28805

M3 - Article

VL - 234

SP - 22400

EP - 22410

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

IS - 12

ER -